This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Laurus Labs Ltd
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of Laurus Labs Ltd (LAURUSLABS)?
Can I buy Laurus Labs Ltd (LAURUSLABS) shares?
How do I buy Laurus Labs Ltd (LAURUSLABS) from Angel One?
- Direct investment: You can buy Laurus Labs Ltd (LAURUSLABS) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Laurus Labs Ltd (LAURUSLABS) shares.
Is Laurus Labs a Debt free Company?
No, Laurus Labs is not a debt free company.
What is the main business of Laurus Labs?
The main business of Laurus Labs is to research, manufacture, and sell pharmaceutical and biotechnology-related products with a special emphasis on Hepatitis C, anti-retroviral, and oncology drugs. It also sells its generic APIs in 56 countries along with generic FDF.
Who are the promoters of Laurus Labs?
Some of the main promoters of Laurus Labs are M/s. NSN Holdings (Represented by its Managing Partner, Dr. Satyanarayana Chava), Chava Naga Rani, Satyanarayana Chava, Chunduru Venkata Lakshmana Rao, Venkata Ravi Kumar Vantaram, Hymavathi Vantaram, Rama Suryadevara, and Krishnaveni Vasireddi.
What are the Subsidiaries that comes under Laurus Labs?
The main subsidiaries that come under Laurus Labs are Laurus Generics Inc., USA, Sriram Labs Pvt. Ltd., Laurus Holdings Ltd., Laurus Ingredients Pvt. Ltd., Laurus Generics Gmbh, Laurus Generics SA (Pty) Ltd., and Laurus Bio Private Ltd. (formerly known as Richcore Lifesciences Pvt. Ltd.).
Today's live share price for Laurus Labs Ltd is NSE: ₹ 341.80, BSE: ₹ 341.85 with a current market capitalization of .
Laurus Labs Limited was originally incorporated as Laurus Labs Private Limited on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007. Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007. Subsequently the name of the company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the Company on February 21, 2012. Further, the company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a leading research and development ("R&D") driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients ("APIs") for select, high-growth therapeutic areas of anti-retrovirals ("ARVs") and Hepatitis C. The company also manufactures APIs in oncology and other therapeutic areas. The company`s strategic and early investments in R&D and manufacturing infrastructure has enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing "donor-funded access-to-medicines markets" of Sub-Saharan Africa, South-East Asia and Latin America. The company also has growing synthesis and nutraceutical/cosmeceutical ingredients businesses. Further, It is increasingly focused towards growing its integrated generics finished dosage forms ("FDFs") business in which it has made significant investments. Laurus Labs operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis and Ingredients. Its Generics - API business comprises the development, manufacture and sale of APIs and advanced intermediates; itsGenerics - FDF business comprises the development and manufacture of oral solid formulations; its Synthesis business includes contract development and manufacturing services for global pharmaceutical companies; and its Ingredients business comprises the manufacture and sale of specialty ingredients for use in the nutraceutical and cosmeceutical sectors. The company has launched 59 products since its inception in 2005. Its key customers include Aspen Pharmacare Limited, Aurobindo Pharma Limited, Cipla Limited, Mylan Laboratories Limited, NATCO Pharma Limited ("NATCO") and Strides Shasun Limited. As of September 30, 2016, the Company owned 34 patents and had 152 pending patent applications, in several countries.Read more